Evidence map›Paper›PMID 28025779›Full record

ArticleHead and neck pathology2017

Correlation of Ki-67 Proliferative Antigen Expression and Tumor Response to Induction Chemotherapy Containing Cell Cycle-Specific Agents in Head and Neck Squamous Cell Carcinoma.

Jonathan Chatzkel, James S Lewis, Jessica C Ley, Tanya M Wildes, Wade Thorstad, Hiram Gay, Mackenzie Daly, Ryan Jackson, Jason Rich, Randal Paniello and 5 more

Abstract read
In one paragraph

Article in Head and neck pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jonathan ChatzkelDepartment of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid, Campus Box 8056, St. Louis, MO, 63110, USA.
James S LewisDepartment of Pathology, Microbiology, and Immunology Vanderbilt University School of Medicine, Nashville, TN, USA.
Jessica C LeyDepartment of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid, Campus Box 8056, St. Louis, MO, 63110, USA.
Tanya M WildesDepartment of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid, Campus Box 8056, St. Louis, MO, 63110, USA.
Wade ThorstadAlvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Hiram GayAlvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Mackenzie DalyAlvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Ryan JacksonAlvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Jason RichAlvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Randal PanielloAlvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Brian NussenbaumAlvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Jingxia LiuDivision of Public Health Sciences, Washington University School of Medicine, St. Louis, MO, USA.
Barry A SiegelAlvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Farrokh DehdashtiAlvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Douglas AdkinsDepartment of Internal Medicine, Division of Medical Oncology, Washington University School of Medicine, 660 South Euclid, Campus Box 8056, St. Louis, MO, 63110, USA. dadkins@wustl.edu.

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
National Cancer Institute P30 CA91842NCI NIH HHS P30 CA091842
6 · The paper itself

Abstract

Determine if highly proliferative head and neck squamous cell carcinomas, assessed by pretreatment Ki-67 expression, respond more robustly to induction chemotherapy (IC) that is selectively toxic to cycling cells. Retrospective analysis of 59 patients treated with IC and chemoradiation. IC included either nab-paclitaxel, cisplatin, 5-FU and cetuximab (APF-C, n = 27) or docetaxel, cisplatin, 5-FU +/- cetuximab (TPF+/-C, n = 32). Ki-67 expression was assessed by immunohistochemistry. Tumor response (complete/partial/stable/progressive) at the primary site after two IC cycles was evaluated by visual examination in all patients. In the APF-C sub-group, tumor response (primary site and neck nodes) after two IC cycles was evaluated by computed tomography (CT) and fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT. Ki-67 expression (median 66%, range: 16-97) did not differ across the tumor response categories assessed by visual examination (p = 0.95), CT (p = 0.30), or FDG-PET/CT (p = 0.65). Median decrease in summed SUV

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Squamous CellCetuximabCisplatinDocetaxelFemaleFluorouracilHead and Neck NeoplasmsHumansInduction ChemotherapyKi-67 AntigenMaleMiddle AgedBiomarkers, TumorCetuximabCisplatinDocetaxelFluorouracilKi-67 AntigenPaclitaxelTaxoidsChemotherapy sensitivityHNSCCKi-67 expression

Identifiers

PMID28025779
PMCPMC5550393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.